Produktname:(R)-4-(2,4-dimethoxybenzyl)-3-methylpiperazin-2-one
IUPAC Name:(3R)-4-[(2,4-dimethoxyphenyl)methyl]-3-methylpiperazin-2-one
- CAS:1383146-20-0
- Molekulare Formel:C14H20N2O3
- Reinheit:95%
- Katalognummer:CM131538
- Molekulargewicht:264.33
Nur für den Einsatz in Forschung und Entwicklung..
Produkt-Details
- CAS-Nr.:1383146-20-0
- Molekulare Formel:C14H20N2O3
- Schmelzpunkt:-
- SMILES-Code:O=C1NCCN(CC2=CC=C(OC)C=C2OC)[C@@H]1C
- Dichte:
- Katalognummer:CM131538
- Molekulargewicht:264.33
- Siedepunkt:436.1±45.0°C at 760 mmHg
- Mdl-Nr.:MFCD22372628
- Lagerung:Store at room temperature.
Category Infos
- Piperazines
- Piperazine is an organic compound consisting of a six-membered ring containing two nitrogen atoms in opposite positions in the ring. The chemical formula of piperazine is C4H10N2, and it is an important pharmaceutical intermediate. Pyrimidines and piperazines are known to be the backbone of many bulk compounds and important core structures for approved drugs; studies have shown that combining a pyridine ring with a piperazine moiety within a single structural framework enhances biological activity.
Column Infos
- Fezolinetant
- Dec 10, 2023, VEOZA (fezolinetant) approved by European Commission for treatment of vasomotor symptoms associated with menopause.
VEOZAH is the first and only neurokinin 3 (NK3) receptor antagonist that blocks NKB from binding on KNDy neurons to help reduce heat signals that trigger VMS. First-in-class fezolinetant brings women a new nonhormonal therapy for hot flashes.
In May 2023, FDA has approved VEOZA(fezolinetant) 45 mg once daily for the treatment of moderate to severe VMS due to menopause.